Research Summary

Selected Publications

• 1. Harada, M., Matsumoto, T., Yamamoto, M., Goda, J., Idei, A., Ohtaki, K., Kojima, N., Yoneda, N., Miyauchi, K., Katsura, K., Ikeda, M., Hanada, K., Ishizuka-Katsura, Y., Hosaka, T., Hisano, T., Kaizuka, T., Yamamoto, T., Matsuda, M., Nakayama, M., Sugimoto-Ishige, A., Sakuma, M., Hashimoto, R., Takayama, K., Nakayama, M., Nguyen, CT., Ishigaki, H., Itoh, Y., Hashizume, Y., Yoshida, M., Kawaguchi, Y., Takeda, M., Koseki, H., Shirouzu, M., Inoue, JI., S and Saito, T.:
  "Monoclonal antibodies against human TMPRSS2 prevent infection by any SARS-CoV-2 variant”
  iScience. 28(9), 113424. (2025).
• 2. Hou, J., Uejima, T., Tanaka, M., Son, Y. L., Hanada, K., Kukimoto-Niino, M., Yamaguchi, S., Hashimoto, S., Yokoyama, S., Takemori, T., Saito, T., Shirouzu, M., and Kondo, T.:
  "EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells"
  Neuro-oncol. 27(3), 682–694. (2024).
• 3. Suzuki, M., Uchibori, K., Oh-hara, T., Nomura, Y., Suzuki, R., Takemoto, A., Araki, M., Matsumoto, S., Sagae, Y., Kukimoto-Niino, M., Kawase, Y., Shirouzu, M., Okuno, Y., Nishio, M., Fujita, N., and Katayama, R.:
  "A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer"
  npj Precision Oncology 8(1), 46. (2024).
• 4. Takeshita, M., Fukuyama, H., Kamada, K., Matsumoto, T., Makino-Okamura, C., Lin, Q., Sakuma, M., Kawahara, E., Yamazaki, I., Uchikubo-Kamo, T., Tomabechi, Y., Hanada, K., Hisano, T., Moriyama, S., Takahashi, Y., Ito, M., Imai, M., Maemura, T., Furusawa, Y., Yamayoshi, S., Kawaoka, Y., Shirouzu, M., Ishii, M., Saya, H., Kondo, Y., Kaneko, Y., Suzuki, K., Fukunaga, K., Takeuchi, T., and the Keio Donner Project:
  "Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents”
  iScience. 26(6), 106955. (2023).
• 5. Takase, S., Hiroyama, T., Shirai, F., Maemoto, Y., Nakata, A., Arata, M., Matsuoka, S., Sonoda, T., Niwa, H., Sato, S., Umehara, T., Shirouzu, M., Nishigaya, Y., Sumiya, T., Hashimoto, N., Namie, R., Usui, M., Ohishi, T., Ohba, S., Kawada, M., Hayashi, Y., Harada, H., Yamaguchi, T., Shinkai, Y., Nakamura, Y., Yoshida, M., and Ito, A.:
  "A specific G9a inhibitor unveils BGLT3 lncRNA as a universal mediator of chemically induced fetal globin gene expression"
  Nat. Commun. 14(1), 23. (2023).
• 6. Takemori, T., Sugimoto-Ishige, A., Nishitsuji, H., Futamura, Y., Harada, M., Kimura-Someya, T., Matsumoto, T., Honma, T., Tanaka, M., Yaguchi, M., Isono, K., Koseki, H., Osada, H., Miki, D., Saito, T., Tanaka, T., Fukami, T., Goto, T., Shirouzu, M., Shimotohno, K., and Chayama, K.:
  "Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection”
  J Virol. 96(5), e0168621. (2022).
• 7. Mizuta, H., Okada, K., Araki, M., Adachi, J., Takemoto, A., Kutkowska, J., Maruyama, K., Yanagitani, N., Oh-Hara, T., Watanabe, K., Tamai, K., Friboulet, L., Katayama, K., Ma, B., Sasakura, Y., Sagae, Y., Kukimoto-Niino, M., Shirouzu, M., Takagi, S., Simizu, S., Nishio, M., Okuno, Y., Fujita, N., and Katayama, R.:
  "Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer”
  Nat Commun. 12(1), 1261. (2021).
• 8. Zyryanova, AF., Kashiwagi, K., Rato, C., Harding, HP., Crespillo-Casado, A., Perera, LA., Sakamoto, A., Nishimoto, M., Yonemochi, M., Shirouzu, M., Ito, T., and Ron D.:
  "ISRIB Blunts the Integrated Stress Response by Allosterically Antagonising the Inhibitory Effect of Phosphorylated eIF2 on eIF2B”
  Mol Cell. 81(1), 88-103.e6. (2021).
• 9. Kobayashi, H., Hatakeyama, H., Nishimura, H., Yokota, M., Suzuki, S., Tomabechi, Y., Shirouzu, M., Osada, H., Mimaki, M., Goto, YI., and Yoshida, M.:
  "Chemical reversal of abnormalities in cells carrying mitochondrial DNA mutations”
  Nat Chem Biol 17(3), 335-343. (2021).
• 10. Yasukawa, M., Ando, Y., Yamashita, T., Matsuda, Y., Shoji, S., Morioka, M., Kawaji, H., Shiozawa, K., Machitani, M., Abe, T., Yamada, S., Kaneko, M. K., Kato, Y., Furuta, Y., Kondo, T., Shirouzu, M., Hayashizaki, Y., Kaneko, S., and Masutomi, K.:
  "CDK1 dependent phosphorylation of hTERT contributes to cancer progression"
  Nat. Commun. 11(1), 1557. (2020).

Related Links

Lab Members

Contact Information